

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Semaglutide for managing overweight and obesity and the reduction of associated cardiovascular risk (ID6441 including a review of TA875 and TA910)

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Novo Nordisk (semaglutide) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • All About Obesity • Blood Pressure UK • British Obesity Society • Cardiomyopathy UK • Cardiovascular Care Partnership • Circulation Foundation • Diabetes UK • Different Strokes • HEART UK • Kidney Care UK • Kidney Research UK • National Kidney Federation • Network of Sikh Organisations • Obesity Empowerment Network • Obesity Health Alliance • Obesity UK • Pumping Marvellous Foundation • Somerville Heart Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Stroke Association • Stroke Information • Weight Concern <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • Association for the Study of Obesity 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health - Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • NHS Wales Joint Commissioning Committee • Scottish Medicines Consortium • Welsh Government <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Biocon Pharma UK (liraglutide) • Eli Lilly (tirzepatide) • Hialeon UK (orlistat) • Neon Healthcare (orlistat) • Novo Nordisk (liraglutide) • Ranbaxy UK (liraglutide) • Zentiva (liraglutide)

Provisional stakeholder list for the evaluation of semaglutide for managing overweight and obesity and the reduction of associated cardiovascular risk (ID6441 including a review of TA875 and TA910)

Issue date: February 2025

© National Institute for Health and Care Excellence 2025. All rights reserved.

1 of 4

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British and Irish Association of Stroke Physicians • British and Irish Hypertension Society • British Association for Nursing in Cardiovascular Care • British Cardiovascular Society • British Dietetic Association • British Geriatrics Society • British Heart Foundation • British Heart Rhythm Society • British Nutrition Foundation • British Obesity & Metabolic Surgery Society • British Society for Haemostasis and Thrombosis • British Society for Heart Failure • British Society for Paediatric Endocrinology and Diabetes • Clinical Leaders of Thrombosis (CLOT) • Faculty of Public Health • National Heart and Lung Institute • Neonatal and Paediatric Pharmacists Group • Nutrition Society • Obesity Management Association • Obesity Specialist Group (BDA) • Primary Care Cardiovascular Society • Royal College of Emergency Medicine • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics & Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Cardiological Science and Technology • Society for Endocrinology • Society for Vascular Nurses • Society for Vascular Technology 	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Cardiovascular Research [BCS affiliated] • Cardiac and Cardiology Research Dept, Barts • Cochrane Heart, Stroke and Circulation • Cochrane Metabolic & Endocrine Disorders Group • Cochrane Public Health Group • European Council for Cardiovascular Research • Genomics England • Heart Research UK • MRC Clinical Trials Unit • National Centre for Cardiovascular Preventions and Outcomes • National Institute for Health Research • Obesity Institute • Wellcome Trust <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

Provisional stakeholder list for the evaluation of semaglutide for managing overweight and obesity and the reduction of associated cardiovascular risk (ID6441 including a review of TA875 and TA910)

Issue date: February 2025

© National Institute for Health and Care Excellence 2025. All rights reserved.

2 of 4

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • UK Clinical Pharmacy Association • Vascular Society of Great Britain and Ireland <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example,

Provisional stakeholder list for the evaluation of semaglutide for managing overweight and obesity and the reduction of associated cardiovascular risk (ID6441 including a review of TA875 and TA910)

Issue date: February 2025

© National Institute for Health and Care Excellence 2025. All rights reserved.

the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.